Efficacy and safety of apatinib treatment for gastric cancer, hepatocellular carcinoma and non-small cell lung cancer: a meta-analysis
J Xue, M Astère, M Zhong, H Lin, J Shen… - OncoTargets and …, 2018 - Taylor & Francis
Apatinib (Aitan®, brand name in China) is a new anti-antiangiogenic agent that has recently
been approved for the treatment of advanced gastric cancer (GC) in China. Nevertheless, its …
been approved for the treatment of advanced gastric cancer (GC) in China. Nevertheless, its …
Apatinib for chemotherapy-refractory extensive-stage SCLC: a retrospective study
H Li, J Zeng, X Jin, X Yu, G Zhou, W Hong - Cancer Chemotherapy and …, 2019 - Springer
Purpose There is no standard treatment strategy for patients with extensive-stage small cell
lung cancer (SCLC) who have failed two or more prior chemotherapeutic regimens. In this …
lung cancer (SCLC) who have failed two or more prior chemotherapeutic regimens. In this …
Angiogenesis and apatinib: Can be used for the patients with non-gastic cancer?
Y Ni, X Ye - Journal of Cancer Research and Therapeutics, 2018 - journals.lww.com
Angiogenesis contributes mainly to malignant tumor growth and metastasis. Since the
1970s, antiangiogenic treatment has been investigated and widely accepted as an effective …
1970s, antiangiogenic treatment has been investigated and widely accepted as an effective …
A triple rare E709K and L833V/H835L EGFR mutation responsive to an irreversible pan-HER inhibitor: a case report of lung adenocarcinoma treated with afatinib
S Frega, PF Conte, M Fassan, V Polo… - Journal of thoracic …, 2016 - jto.org
1. Zhang Y, Sheng Jin, Kang S, et al. Patients with exon 19 deletion were associated with
longer progression-free survival compared to those with L858R mutation after first-line …
longer progression-free survival compared to those with L858R mutation after first-line …
Sintilimab plus anlotinib as second‐or third‐line therapy in metastatic non‐small cell lung cancer with uncommon epidermal growth factor receptor mutations: A …
K Chen, Y Xu, Z Huang, X Yu, W Hong, H Li… - Cancer …, 2023 - Wiley Online Library
Background Patients with non‐small‐cell lung cancer (NSCLC) and uncommon EGFR
alterations typically have worse treatment outcomes than patients with classically EGFR …
alterations typically have worse treatment outcomes than patients with classically EGFR …
Camrelizumab combined with apatinib and nanoparticle albumin-bound paclitaxel in lung adenocarcinoma (CAPAP-lung): a single-arm phase II study
X Pu, G Lin, M Xiao, J Lin, Q Wang, Y Kong, X Yan… - …, 2024 - thelancet.com
Background Platinum-doublet chemotherapy plus immunotherapy has been the standard of
care for the first-line treatment of advanced non-small cell lung cancer lacking actional driver …
care for the first-line treatment of advanced non-small cell lung cancer lacking actional driver …
LBA66 Afatinib versus chemotherapy for treatment-naïve non-small cell lung cancer with a sensitizing uncommon epidermal growth factor receptor mutation: A phase …
S Miura, H Tanaka, T Misumi, H Yoshioka… - Annals of …, 2023 - annalsofoncology.org
Background EGFR mutations are diverse and include major uncommon and compound
mutations. There is no conclusion on whether EGFR-TKI is the optimal treatment for these …
mutations. There is no conclusion on whether EGFR-TKI is the optimal treatment for these …
A case report of advanced lung adenocarcinoma harboring KRAS mutation treated with anlotinib
SU Yudong, M Zhaoting, XU Xiaoyan… - Zhongguo Fei Ai …, 2018 - search.proquest.com
近年来, 晚期非小细胞肺癌 (non-small cell lung cancer, NSCLC) 患者逐渐增多,
治疗方法也明显增多, 然而, 目前对于靶向治疗表皮生长因子受体 (epidermal growth factor …
治疗方法也明显增多, 然而, 目前对于靶向治疗表皮生长因子受体 (epidermal growth factor …